The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
Ontology highlight
ABSTRACT: Over the past decade, immunotherapy has emerged as one of the most promising approaches to cancer treatment. The use of immune checkpoint inhibitors has resulted in impressive and durable clinical responses in the treatment of various cancers. Additionally, immunotherapy utilizing chimeric antigen receptor (CAR)-engineered T cells has produced robust responses in blood cancers, and T cell receptor (TCR)-engineered T cells are showing promising results in the treatment of solid cancers. Despite these noteworthy advancements in cancer immunotherapy, numerous challenges remain. Some patient populations are unresponsive to immune checkpoint inhibitor therapy, and CAR T cell therapy has yet to show efficacy against solid cancers. In this review, we first discuss the significant role that T cell
SUBMITTER: Chen C
PROVIDER: S-EPMC10218245 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA